| Corporate-sponsored trial |
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. |
Department of Medical Oncology |
| Corporate-sponsored trial |
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION Study) |
Department of Neurosurgery |
| Corporate-sponsored trial |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION-Breast04) |
Department of Breast Surgery |
| Corporate-sponsored trial |
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) (CYTB323J12201) |
Department of Rheumatology and Clinical Immunology |
| Corporate-sponsored trial |
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (EvoPAR-Breast01) |
Department of Breast Surgery |
| Corporate-sponsored trial |
A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors. |
Department of Neurosurgery |
| Investigator-initiated trial |
Phase I Single-Administration Study of TRG035 in Healthy Adults |
Department of Early Clinical Development |
| Corporate-sponsored trial |
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer |
Department of Breast Surgery |
| Corporate-sponsored trial |
[M24-742]First-in-Human Study of ABBV-969 in Metastatic Castration-Resistant Prostate Cancer |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (J5A-OX-JZWA) |
Department of Early Clinical Development |
| Corporate-sponsored trial |
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2) |
Department of Medical Oncology |
| Corporate-sponsored trial |
PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC（CAAA617D12302）. |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1) |
Department of Hematology |
| Corporate-sponsored trial |
Phase I Study of AK1910 in Healthy Japanese Subjects, Healthy Caucasian Subjects, Patients with Systemic Lupus Erythematosus (Single Dose and Multiple Dose Study) |
Department of Rheumatology and Clinical Immunology |
| Investigator-initiated trial |
Investigator-initiated phase 1 trial of antisense oligonucleotide against TUG1 for recurrent glioblastoma (TUG trial) |
Department of Neurosurgery |
| Corporate-sponsored trial |
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies |
Department of Hematology |
| Corporate-sponsored trial |
[M23-385]A Phase 1 study of ABBV-706 alone or in combination in adult subjects with advanced solid tumors. |
Department of Early Clinical Development |
| Corporate-sponsored trial |
[M24-427]ABBV-400 in Select Advanced Solid Tumor Indications |
Department of Early Clinical Development |
| Corporate-sponsored trial |
[M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous（IV）ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) |
Department of Respiratory Medicine |
| Corporate-sponsored trial |
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) |
Department of Breast Surgery |
| Corporate-sponsored trial |
AB122 Platform study |
Department of Medical Oncology |
| Corporate-sponsored trial |
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers（HERIZON-GEA-01） |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy（TROPION-Breast03） |
Department of Breast Surgery |
| Investigator-initiated trial |
A Phase 1 Study of Lomustine and PCV in Japanese Patients with Glioma（LOMG） |
Department of Neurosurgery |
| Investigator-initiated trial |
PRIME Study (PRIME Study) |
Department of Nephrology |
| Investigator-initiated trial |
NCCH2101/MK011 trial (Perfume trial) |
Department of Medical Oncology |
| Corporate-sponsored trial |
Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
Department of Hematology |
| Investigator-initiated trial |
Phase II Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic Therapy |
Department of Medical Oncology |
| Investigator-initiated trial |
NCCH2201/MK013 trial (CRYSTAL trial) |
Department of Hematology |
| Corporate-sponsored trial |
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (BB2121-EAP-001) |
Department of Hematology |
| Corporate-sponsored trial |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants with Advanced Solid Tumors Receiving Intravenous（IV） ABBV-400 |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPC (CAAA617A11201) |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release (JCAR017-EAP-001) |
Department of Hematology |
| Investigator-initiated trial |
PENETRATE |
Department of Medical Oncology |
| Investigator-initiated trial |
Clinical Trial of Alectinib in Patients with ALK positive rare cancer |
Department of Medical Oncology |
